Key Takeaway
After 1 year on Wegovy, most patients lose 28 to 42 pounds at the 2.4 mg maintenance dose. Here is a complete 12-month timeline with STEP trial data.
One year on Wegovy represents the full realization of what this notable medication can do. Patients researching Wegovy results after 1 year can expect a total weight loss of 28 to 42 pounds, representing approximately 12% to 16% of their starting body weight . At the 2.4 mg maintenance dose, Wegovy has delivered seven to eight months of sustained peak-dose therapy, and the results speak for themselves.
One-Year Results: The Complete Picture
| Outcome | Typical Range at 1 Year |
|---|---|
| Total weight loss | 28 to 42 pounds |
| Body weight percentage lost | 12% to 16% |
| Waist circumference | 5 to 8 inches lost |
| Systolic blood pressure | 8 to 16 mmHg decrease |
| Triglycerides | 20% to 35% decrease |
| CRP (inflammation) | 30% to 55% decrease |
| Quality of life score | Significantly improved |
The landmark STEP 1 trial[1] reported 14.9% body weight[1] loss at 68 weeks for the semaglutide 2.4 mg group, with approximately 13% to 14% achieved by week 52 . The STEP 3 trial[2], which combined Wegovy with intensive behavioral therapy, showed even greater results at 16% weight loss, highlighting the benefit of combining medication with lifestyle support .
12-Month Milestone Markers
| Milestone | When | What It Means |
|---|---|---|
| 5% body weight loss | Month 3 | Clinically meaningful. Reduces diabetes risk. |
| 10% body weight loss | Month 5 to 6 | Major health improvements. Reduced cardiovascular risk. |
| 15% body weight loss | Month 9 to 12 | significant. Approaches surgical-level outcomes. |
| Near-maximum weight loss | Month 12 to 15 | Weight stabilizing at new baseline. |
Each milestone brings progressively greater health benefits. The 10% threshold is particularly significant because it's associated with reductions in cardiovascular events, diabetes prevention, and improvements in sleep apnea, joint pain, and fatty liver disease . For a complete cost breakdown, see our semaglutide pricing comparison.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
The Cardiovascular Story
Wegovy isn't just a weight loss medication. It's the first obesity treatment proven to reduce cardiovascular events :
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- The SELECT trial[3] enrolled over 17,000 overweight adults with established cardiovascular disease
- Semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by 20%
- This benefit was observed as early as month 6 and persisted throughout the trial
- Wegovy received an expanded FDA indication for cardiovascular risk reduction in March 2024
This means your year on Wegovy hasn't only changed how you look and feel but has actively protected your heart and blood vessels.
What Happens After One Year
The year-one milestone prompts important decisions about your treatment future :
- Continuing treatment: Most patients benefit from ongoing therapy. Weight loss is maintained as long as treatment continues.
- Dose improvement: Some patients maintain results at 1.7 mg instead of 2.4 mg, reducing cost without sacrificing efficacy.
- Cost management: Switching to compounded semaglutide can make long-term treatment more affordable FormBlends pricing.
- Structured discontinuation: If stopping, a gradual taper with close weight monitoring and lifestyle support gives the best chance of maintaining some results.
The STEP 1 extension study showed that patients who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year . This finding has led most obesity medicine experts to recommend continued treatment for patients who are benefiting.
Long-Term Monitoring Checklist
- Annual thorough blood work. Metabolic panel, lipids, A1C, CBC, thyroid, vitamin D, B12, iron, and inflammatory markers.
- Body composition testing. DEXA scan to assess lean mass, fat mass, and bone density changes.
- Cardiovascular screening. Blood pressure monitoring, possible cardiac risk assessment.
- Nutritional assessment. Evaluate dietary adequacy and supplement needs.
- Mental health evaluation. Assess body image adjustment, emotional wellbeing, and quality of life.
- Exercise program review. Ensure your fitness routine supports long-term health and muscle preservation FormBlends telehealth consultation.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Is Wegovy at one year as effective as bariatric surgery?
Wegovy produces about 15% total body weight loss on average, compared to 25% to 35% for surgical procedures. While not equivalent to surgery, Wegovy avoids surgical complications and offers proven cardiovascular benefits .
What percentage of patients keep the weight off after one year?
Patients who continue Wegovy maintain their weight loss. Among those who stop, about one-third maintain significant weight loss through lifestyle changes, while two-thirds experience substantial regain .
Can I take Wegovy indefinitely?
Current evidence supports long-term use. The FDA approval doesn't specify a maximum treatment duration. Your provider will help you evaluate the benefits and risks of continued treatment annually.
Is switching to compounded semaglutide a good option for year two?
Yes. Compounded semaglutide contains compounded formulations of the active ingredient at a lower cost, making long-term treatment more financially sustainable. FormBlends offers smooth transitions from brand-name to compounded products $1,300-$1,400/mo (brand) FormBlends pricing.
What new medications might become available during year two?
The GLP-1 field is evolving rapidly. Triple-agonist medications like retatrutide and oral formulations of existing medications are in advanced clinical trials. Your provider can help you evaluate new options as they become available .